CASIRIVIMAB AND IMDEVIMAB
CASIRIVIMAB AND IMDEVIMAB
Authorization By Interim Order Revoked
DIN Number
02516705
Drug Class
Human
Market Date
Jul 29, 2021
Company
HC
Hoffmann-La Roche Limited
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02516705
AIG Number0262970001
Classification & Schedule
C
Drug Class
Human
S
Schedule
COVID-19 - IO - Authorization
,
Prescription
,
Schedule D
A
ATC Code
J06BD07 CASIRIVIMAB AND IMDEVIMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
AHFS Classification08:18.24
Health Canada Classification
ACTIVE INGREDIENTS (2)
CASIRIVIMABActive
Strength: 1332 MG / 11.1 ML
Monograph: CASIRIVIMAB
IMDEVIMABActive
Strength: 1332 MG / 11.1 ML
Monograph: IMDEVIMAB